

1-27-2022

Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial.

Andrew J Song

Keyue Ding

Iyad Alnahhas

Normand J Laperriere

James Perry

See next page for additional authors

Follow this and additional works at: <https://jdc.jefferson.edu/radoncfp>



Part of the [Oncology Commons](#), and the [Radiation Medicine Commons](#)

[Let us know how access to this document benefits you](#)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Radiation Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Andrew J Song, Keyue Ding, Iyad Alnahhas, Normand J Laperriere, James Perry, Warren P Mason, Chad Winch, Chris J O'Callaghan, Johan J Menten, Alba A Brandes, Claire Phillips, Michael F Fay, Ryo Nishikawa, David Osoba, J Gregory Cairncross, Wilson Roa, Wolfgang Wick, and Wenyin Shi

Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial

Andrew J. Song, Keyue Ding, Iyad Alnahhas, Normand J. Laperriere, James Perry, Warren P. Mason, Chad Winch, Chris J. O’Callaghan, Johan J. Menten, Alba A. Brandes, Claire Phillips, Michael F. Fay, Ryo Nishikawa, David Osoba, Gregory Cairncross, Wilson Roa, Wolfgang Wick, and Wenyin Shi

Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA (A.J.S., W.S.); Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA (I.A.); Department of Public Health Sciences, Canadian Cancer Trials Group, Kingston, Ontario, Canada (K.D., C.W., C.J.O.); Department of Radiation Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada (N.J.L.); Department of Medicine, Division of Neurology, University of Toronto, Toronto, Ontario, Canada (J.P.); Department of Experimental Radiation Oncology, University Hospitals Leuven, Leuven, Belgium (J.J.M.); Department of Medical oncology, IRCCS Istituto Scienze Neurologiche – Bologna, Italy (A.A.B.); Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia (C.P.); Genesis Cancer Care, Newcastle, NSW, Australia (M.F.); Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Hidaka, Japan (R.N.); QOL Consulting, West Vancouver, British Columbia, Canada (D.O.); Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada (G.C.); Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada (W.R.); Division of Neurooncology, Heidelberg University Medical Center, Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany (W.W.)

Corresponding Author: Wenyin Shi, MD, PhD, Department of Radiation Oncology, Thomas Jefferson University, 111 S 11th St, G-301, Philadelphia, PA 19107, USA (Wenyin.Shi@Jefferson.edu).

When this paper was first published, the clinical trial number “TROG 03.01” was incorrect in the title and second paragraph. It should be it should have been “TROG 08.02”. This has now been corrected online.